logo
#

Latest news with #PatrickBarry

Indivior PLC (INDV) Reinvents Leadership, Moves Listing to Nasdaq
Indivior PLC (INDV) Reinvents Leadership, Moves Listing to Nasdaq

Yahoo

timea day ago

  • Business
  • Yahoo

Indivior PLC (INDV) Reinvents Leadership, Moves Listing to Nasdaq

We recently compiled a list of Indivior PLC stands seventh on our list among the best mid cap stocks according to billionaires. Indivior PLC (NASDAQ:INDV) is a pharmaceutical company focused on opioid addiction treatment, particularly through its flagship product SUBLOCADE, a monthly buprenorphine injection. The company has demonstrated strong growth and resilience, recently reaching a 52-week stock high. In 2025, Indivior PLC (NASDAQ:INDV) underwent a strategic leadership overhaul to strengthen its market position in the U.S., the primary arena for its operations. Joe Ciaffoni took over as CEO, bringing a fresh vision to the company, while Patrick Barry joined as Chief Commercial Officer to drive commercial expansion, especially around SUBLOCADE. Tony Kingsley also joined the board to enhance governance. These changes reflect a focused effort to boost performance and align leadership with U.S. market priorities. In line with this strategy, the business announced its plan to shift its primary listing from the London Stock Exchange to Nasdaq, aiming for greater visibility and investor engagement in the American market. Photo by Matteo Badini on Unsplash On the clinical front, Indivior PLC (NASDAQ:INDV) presented new findings at the 2025 CPDD meeting showing that higher buprenorphine exposure may improve treatment outcomes in patients with high fentanyl use, a critical step given the ongoing fentanyl crisis. The FDA also approved updated labeling for SUBLOCADE, further expanding its clinical utility. While we acknowledge the potential of INDV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.

Indivior PLC (INDV) Reinvents Leadership, Moves Listing to Nasdaq
Indivior PLC (INDV) Reinvents Leadership, Moves Listing to Nasdaq

Yahoo

timea day ago

  • Business
  • Yahoo

Indivior PLC (INDV) Reinvents Leadership, Moves Listing to Nasdaq

We recently compiled a list of Indivior PLC stands seventh on our list among the best mid cap stocks according to billionaires. Indivior PLC (NASDAQ:INDV) is a pharmaceutical company focused on opioid addiction treatment, particularly through its flagship product SUBLOCADE, a monthly buprenorphine injection. The company has demonstrated strong growth and resilience, recently reaching a 52-week stock high. In 2025, Indivior PLC (NASDAQ:INDV) underwent a strategic leadership overhaul to strengthen its market position in the U.S., the primary arena for its operations. Joe Ciaffoni took over as CEO, bringing a fresh vision to the company, while Patrick Barry joined as Chief Commercial Officer to drive commercial expansion, especially around SUBLOCADE. Tony Kingsley also joined the board to enhance governance. These changes reflect a focused effort to boost performance and align leadership with U.S. market priorities. In line with this strategy, the business announced its plan to shift its primary listing from the London Stock Exchange to Nasdaq, aiming for greater visibility and investor engagement in the American market. Photo by Matteo Badini on Unsplash On the clinical front, Indivior PLC (NASDAQ:INDV) presented new findings at the 2025 CPDD meeting showing that higher buprenorphine exposure may improve treatment outcomes in patients with high fentanyl use, a critical step given the ongoing fentanyl crisis. The FDA also approved updated labeling for SUBLOCADE, further expanding its clinical utility. While we acknowledge the potential of INDV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store